Cellevate appoints bioprocessing industry expert Bettina Berendsen as Board Observer and Strategic Advisor
LUND, Sweden – Cellevate AB, an innovative biotech company developing the next generation of cell culture systems based on nanotechnology, is pleased to announce the appointment of Bettina Berendsen as Board of Directors Observer as well as Strategic Advisor. Bettina Berendsen is an executive leader with over 35 years of extensive experience in the global biopharmaceutical and life science industry, encompassing both commercial and technical aspects. Her broad experience includes sales, strategy, and organizational development, negotiation, leading change and mergers and acquisitions. Bettina Berendsen spent over 34 years with Sartorius Stedim Biotech, where she held various positions including Head of Sales & Service, Head of Key Accounts and Vice President Europe. Prior to joining Sartorius, she was Head of Analytics at LFP Munich. Bettina serves on the advisory boards of NanoTemper Technologies and the Fraunhofer Institute for Cell Therapy and Immunology IZI.
“Great to be joining Cellevate at such an exciting time in the company, as we prepare the final steps before commercialization in the bioprocessing industry. The company’s innovative cell culture products have the potential to make a significant impact on the future of upstream bioprocessing and contribute to decrease costs of biomanufacturing of cell and gene therapy and novel vaccines”, says Bettina Berendsen.
“We are delighted to have Bettina Berendsen join us both as Board Observer as well as Strategic Advisor at this pivotal moment for Cellevate. Bettina´s extensive industrial network, and experience in leading large-scale sales strategies and organizational development in Europe and North America, is a fantastic contribution for Cellevate as we now have entered the commercial stage in bioprocessing by launching our first product, Cellevat3d™ nanofiber microcarriers in November 2024”, says Laura Chirica, CEO Cellevate.
More information about Cellevate’s Scientific & Industrial Advisory Board members.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d™ is a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber microcarriers – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d™ microcarriers products are designed as an integrated part of upstream bioprocess solutions, from laboratory to large-scale batch production. Cellevat3d™ nanofiber microcarriers have a commercial launch and sales start in November 2024.
For more information, please visit www.cellevate.com.